Introduction and aims
Steroids are widely used by living organisms for transmitting information in a chemical way. These compounds of different structures with hormonal action have a very important role in regulating the essential processes of cells, therefore any molecule involved in the production, dissimilation, modification, transport of these compounds or can bind to them can be used as potential agents in medications. Nowadays conjugation of an effective steroid with a biomolecule common in nature, e.g. a carbohydrate or a nucleoside unit, becomes more and more popular method for the enhancement of selectivity. This bioconjugation approach is already used by Nature; and it has been found that the biological potency of these new hybrids may exceed that of the parent compounds.
Estrogen is responsible for the development of secondary female character, plays a role in the thickening of the endometrium and in the regulation of the menstrual cycle. The oxygen atoms in the molecule are at a well-defined distance which plays an important role in the estrogen and estradiol hormone activity. Chemical modifications of estrone may lead to compounds lacking hormonal behavior which is a key aspect of the development of steroid based anticancer agents.
Substitution at C-2, opening of ring D or inversion at C-13 of the estrane skeleton usually leads to the loss of estrogenic activity. We know from initial results that secosteroid derivatives and the 13α isomers are ideal for incorporating further modifications and for forming conjugates.
In my doctoral work, I planned to synthesize carbohydrate-and nucleoside-containing bioconjugates of these steroids with already established antiproliferative properties and investigate how the conjugation affects the strength of the anticancer activity and selectivity.
The purpose of our work was to synthesize estrone-monosaccharide and estron-nucleoside conjugates, in which the two components are linked in a click reaction. In the case of monosaccharides, development of the azide functional group was designed to replace the glycosidic or primary, while for nucleosides the 5'-hydroxy group. The azide derivatives produced this way were expected to react with the estrone derivatives (D-secoestrone, 13α and β-estrone) containing the propargyl functional group at positions 3 or 15, previously obtained by the Steroid Chemistry Research Group, in the presence of a copper(I) catalyst.
The new conjugates were planned to be evaluated in vitro by means of MTT assays for antiproliferative activity; and their potential inhibitory activity on human 17β-HSD1 enzyme was anticipated to be investigated.
Experimental methods
All solvents were distilled prior to use. Reagents and materials were obtained from commercial suppliers and were used without purification. Melting points (mp) were determined on a Kofler block and Electrothermal IA8103 apparatus and are uncorrected. 
3.4.
In case of two glucose-containing bioconjugates (65a,b), which showed the best biological activities, the acetyl protecting groups were removed by Zemplén's method using sodium methylate in methanol to obtain their unprotected derivatives (71a,b, Scheme 3).
Scheme 3. The synthesis of monosaccharide-D-secoestrone bioconjugates (65-71). Reagents: (i)
CuI, (Ph) 3 P, DIPEA, toluene, reflux; (ii) NaOMe, MeOH.
3.5.
For the preparation of 5'-azido-2',5'-dideoxynucleosides (80a-c, Scheme 4), first we have followed the tosyl-azide replacement method based on the literature, but the isolated yields were significantly lower in our hands owing to the formation of by-products compared to those described in the literature therefore we protected the 3'-hydroxy groups. We have chosen acetyl protection of were complete in one day at 50 °C according to TLC and the final isolated yields of protected conjugates (83a-c) were acceptable.
3.7.
Aqueous ammonia is commonly used for the deprotection of these protecting groups in the nucleic acid chemistry but the protected conjugates were not soluble in the aqueous media therefore this deprotection method failed. We have tested the Zemplén deacetylation protocol using 0.1 M of sodium methylate in methanol but only the acetyl group was removed from the 3'-hydroxy group.
Finally, 4 M ammonia solution in methanol was used at 50 °C which removed all the acyl protecting groups of the conjugates (83a-c) in 16 hours to yield the conjugates (84a-c, Scheme 5). 3.14. More nucleoside building blocks have been prepared according to the foregoing methods, which may be suitable for the production of nucleoside containing bioconjugates. The protected forms of the two most sensitive purine-based nucleosides (2'-deoxyadenosine 78a and guanosine 89b, Scheme 9) were chosen as starting materials and versatile linkers (100-104) were attached to the nitrogen atom of the carbamate/thiocarbamate functional group on the 5'-hydroxy: alkyl amidoalkyl, alkylene and oligoethylene glycol. These linkers were coupled to the nucleosides in the way described above (105a-113a, 114b-118b ).
Scheme 9. Synthesis of 5'-linker-containing 2'-deoxyadenosine and guanosine derivatives (105a-113a, 114b-118b and 119a-127a, 128b-132b). Reagents: (i) CDI or thiocarbonyldiimidazole (90), DMAP, DMF; (ii) linker (100-104); (iii) NH 3 /MeOH. 
